Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.56 |
| ▸ | WIZ | O95785 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24675552 | 0.97 | CRBN (0.59) | IKZF2CRBNWIZCSNK1A1ESR1 | |
| SCHEMBL27302543 | 0.97 | CRBN (0.59) | IKZF2CRBNWIZCSNK1A1ESR1 | |
| SCHEMBL27302560 | 0.93 | IKZF2 (0.56) | IKZF2CRBNWIZCSNK1A1ESR1 | |
| SCHEMBL30942549 | 0.93 | IKZF2 (0.56) | IKZF2CRBNWIZCSNK1A1ESR1 | |
| SCHEMBL20235035 | 0.91 | CRBN (0.56) | IKZF2CRBNWIZCSNK1A1ESR1 | |
| SCHEMBL29648403 | 0.90 | CRBN (0.58) | IKZF2CRBNWIZCSNK1A1ESR1 | |
| SCHEMBL24501883 | 0.90 | CRBN (0.58) | IKZF2CRBNWIZCSNK1A1ESR1 | |
| SCHEMBL20372613 | 0.90 | CRBN (0.58) | IKZF2CRBNWIZCSNK1A1ESR1 | |
| SCHEMBL27302697 | 0.90 | CRBN (0.55) | IKZF2CRBNWIZCSNK1A1ESR1 | |
| Hydrochloric Acid SCHEMBL31181025 | 0.90 | CRBN (0.57) | IKZF2CRBNWIZCSNK1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626555-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024118966-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. (US) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | IKZF2 2350/4885CRBN 298/4885WIZ 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.